Navigation Links
Thoratec Reports 44 Percent Increase in Second Quarter Revenues;
Date:7/31/2008

Securities classified as long term investments.

The company also provided a breakdown of sales by product line year-to-date for both of its divisions. The Cardiovascular Division year-to-date revenue was $97.7 million. HeartMate II and HeartMate(R) XVE product sales were $69.0 million, an increase of 59 percent year-over-year. PVAD and IVAD product line sales were $22.0 million, a decrease of two percent year-over year. CentriMag(R) sales were $5.4 million, an increase of 108 percent year-over-year, and graft sales were $1.3 million, consistent with prior year.

The ITC Division year-to-date revenue was $49.3 million. Hospital point-of-care revenues, which include HEMOCHRON coagulation, AVOX co-oximetry and IRMA(R) blood gas products, were $27.2 million, an increase of 16 percent year-over-year. Alternate site revenues, which are primarily from ProTime sales, were $13.8 million, a seven percent increase over last year, while skin incision revenues were $8.3 million, a decrease of three percent versus last year.

GUIDANCE FOR FISCAL 2008

The following statements are based on current expectations. These statements are forward-looking and actual results may differ materially. For a more detailed discussion of forward looking statements, please see additional information below. The company provided an update to guidance for the full year. Revenues are projected to be between $285 million and $295 million. GAAP gross margins are expected to be between 58% and 59%, with non-GAAP gross margins between 59% and 60%. GAAP EPS is expected to be between $0.20 and $0.26, while non-GAAP EPS is expected to be in a range of $0.47 to $0.52.

CONFERENCE CALL/WEBCAST INFORMATION

Thoratec will hold a conference call to discuss its financial results and operating activities for all interested parties at 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight Time) today. The teleconference can be accessed by calling (913) 312-0379, passcode 4
'/>"/>

SOURCE Thoratec Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine news :

1. Thoratec Schedules Second Quarter 2008 Conference Call, Webcast
2. Thoratec Schedules First Quarter 2008 Conference Call, Webcast
3. Thoratec Announces Unanimous FDA Advisory Panel Recommendation for Approval of HeartMate II(R) for Bridge-to-Transplantation
4. URGENT Thoratec Corporation Worldwide Recall of Implantable Ventricular Assist Device
5. Thoratecs ITC Division Receives FDA Warning Letter
6. Thoratec Schedules Third Quarter Conference Call, Webcast
7. HCA Reports Second Quarter 2008 Results
8. Encision Reports First Fiscal Quarter Results
9. Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
10. Orchid Cellmark Reports Second Quarter 2008 Financial Results
11. Nutraceutical Reports Q3 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 24, 2013 Mike Stoler believes that ... successful business people in New York. That’s why ... weekly on CUNY TV. And that’s why he ... Allergy Associates, LLP (ENTA)—the largest single specialty practice in ... throat, allergy and audiology specialists and sub-specialists service communities ...
(Date:5/24/2013)... May 24, 2013 According to a May ... Social Media Leads to Spikes in Plastic Surgery ... a growing prevalence of facial plastic surgery and ... people have become keenly aware of the need to look ... as Facebook, Google and even Skype's video chat feature (Go ...
(Date:5/24/2013)... one in five parents think they have little control ... illicit drug use, a new U.S. government survey finds. ... Abuse and Mental Health Services Administration (SAMHSA), since new ... most influential forces helping to shape their child,s views ... show that parents can make an enormous difference in ...
(Date:5/24/2013)... aortic valve implantation (TAVI) is effective and safe in ... results from a multicentre Asian registry reported at EuroPCR ... a treatment option for selected patients with symptomatic severe ... North American or European centres," Paul Chiam, senior consultant ... conference. He explained that it is unknown whether the ...
(Date:5/24/2013)... Fit Yummy Mummy, a fitness program that ... trying to get rid of the belly fat in ... women who want to combine exercises with nutrition has ... Stevenson, prompting an investigative review. , “Holly's Rigsby's program ... variety of motivational strategies, nutritional plans, proper diets, and ...
Breaking Medicine News(10 mins):Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 2Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 3Health News:Robert Glazer, Chief Executive Officer of ENT and Allergy Associates, LLP®, Talks About the Business of Succeeding in New York 4Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Parents Underestimate Influence Over Teens' Substance Abuse: Survey 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Fit Yummy Mummy: Review Examining Holly Rigsby’s Fitness Program Released 2
... Washington, D.C., and Meet with Elected,Officials, WASHINGTON, March ... Washington, D.C., this April 1 to meet with,congressional leaders ... Disabilities Act, support for epilepsy public health,programs and more ... is one of 50 young people with epilepsy participating ...
... D.C., and Meet With Elected,Officials, WASHINGTON, March 14 ... D.C., this April 1 to meet with,congressional leaders and ... Act, support for epilepsy public health,programs and more research ... one of 50 young people with epilepsy participating in,Kids ...
... DENVER, March 14 Birner Dental Management,Services, Inc. ... dental practices,announced its regular quarterly dividend. The Company,s ... of 17 cents per share of common,stock. The ... of record,March 28, 2008., Birner Dental Management ...
... ( http://www.nhs.uk ), the,digital ,front door, to ... package on,pregnancy, aimed at helping people find ... Based on NHS accredited information, the pregnancy ... staying healthy and fit during pregnancy,including eating ...
... STE ) today announced that its Board ... $300 million in shares of STERIS common stock. ... of,February 29, 2008. This share repurchase authorization replaces ... Through March,13, 2008, the Company has repurchased approximately ...
... that processed vermiculite tainted with asbestos-like fibers that originated from ... and thickening of the membrane that lines the chest wall ... those who were exposed at or below current legal levels. ... times its original size when rapidly heated and has a ...
Cached Medicine News:Health News:Utah Youth Named National Epilepsy Spokesperson 2Health News:Tennessee Youth Named National Epilepsy Spokesperson 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 2Health News:STERIS Corporation Announces New $300 Million Share Repurchase Authorization 3Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 2Health News:Legal exposure to asbestos-like material linked to lung damage 25 years later 3
(Date:5/23/2013)... 23, 2013 Nephros, Inc. (OTC Bulletin Board: ... company that develops and sells high performance liquid purification ... offering.  In addition, the concurrent temporary reduction in exercise ... May 17, 2013. Nephros estimates that it ... rights offering.   A portion of the proceeds will be ...
(Date:5/23/2013)... May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... technology company, today scheduled a conference call to discuss ... year 2013, ended April 30, 2013. The call will ... 2013. The Company will report financial results for the ... close on Thursday, May 30, 2013. ...
(Date:5/23/2013)... Tenn. , May 23, 2013  TeamHealth ... 24-hour nurse triage and nurse advice lines, announces ... committee, comprising physician, nursing and administrative leaders, provides ... safe, quality and cost-effective services for hospital clients, ... our national healthcare system evolves, it,s imperative to ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2TeamHealth Medical Call Center Forms Clinical Advisory Committee 2
... High-dose ursodeoxycholic acid detrimental for treatment of primary sclerosing cholangitis ... national team of researchers led by scientists at Mayo Clinic has ... liver disease, is not helpful for patients, according to a study ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20090105/MAYOLOGO ...
... , ZURICH, Aug. 27 /PRNewswire/ -- ... of four phase III trials have been published in the prestigious peer-reviewed ... roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations ... COPD is an under-diagnosed progressive lung disease that may lead ...
Cached Medicine Technology:Researchers Find High-Dose Therapy for Liver Disease Not Effective 2Researchers Find High-Dose Therapy for Liver Disease Not Effective 3Researchers Find High-Dose Therapy for Liver Disease Not Effective 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 2Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 3Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 4Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 5Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 6Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 7Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 8Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations 9
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: